Serina Therapeutics Inc.

SER | AMEX

Price Alert Chart Builder DCF Calculator

$2.33

+$0.02 (+0.87%)

Sep 22, 2026, 12:32 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.87%

(1D)

Rating

Updated: Aug 17, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $34.94M

1D Range

2.16 2.42

52W Range

1.22 5.83

Valuation (TTM)

PE -1.23

PB 1.85

EV/EBITDA -0.53

Valuation (NTM)

Forward PE N/A

Forward PEG 0.05

Price Target $8

Cash Flow

FCF Yield -61.1%

SBC Adj. FCF Yield -70.0%

SBC Impact -14.5%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -144.0% | -0.1%

Dil EPS 3Y | 5Y 47.5% | 41.0%

FCF 3Y | 5Y -33.1% | -33.7%

Returns

ROA -82.0%

ROE -222.4%

ROIC -116.4%

Financial Health

Net Cash

$22.9M

Current Ratio 6.65

Interest Coverage -117.72

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate inten...

Sector Healthcare

Industry Biotechnology

Employees 16

IPO Date Nov 27, 2018

Website serinatherapeutics.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+243.35%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞